Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

BACKGROUND: Psoriasis, a chronic disease usually requires long‐term disease management. OBJECTIVE: This study evaluates the efficacy and safety of recommended ixekizumab (IXE) dose over 4 years (204 weeks) from UNCOVER‐3 study. METHODS: UNCOVER‐3 was a randomised, double‐blind, multicenter, phase 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebwohl, M.G., Gordon, K.B., Gallo, G., Zhang, L., Paul, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028252/
https://www.ncbi.nlm.nih.gov/pubmed/31479549
http://dx.doi.org/10.1111/jdv.15921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028252/
https://www.ncbi.nlm.nih.gov/pubmed/31479549
http://dx.doi.org/10.1111/jdv.15921

Ejemplares similares